98612-60-3

Basic information

• Product Name: (R)-5-BROMOMETHYL-2-PYRROLIDINONE
• Synonyms: (5R)-5-(broMoMethyl)pyrrolidin-2-one;(R)-5-(BroMoMethyl)pyrrolidin-2-one;(R)-5-BROMOMETHYL-2-PYRROLIDINONE;2-Pyrrolidinone, 5-(bromomethyl)-, (5R)-;[R,(+)]-5α-(Bromomethyl)pyrrolidine-2-one;[R,(+)]-5α-Bromomethyl-2-pyrrolidone;B50370
• CAS NO: 98612-60-3
• Molecular Formula: C₅H₈BrNO
• Molecular Weight: 178.03
• Product Categories: pharmacetical
• Mol File: 98612-60-3.mol

Chemical Properties

• Melting Point: 76-80°C
• Boiling Point: 336.1 °C at 760 mmHg
• Flash Point: 157.1 °C
• Appearance: /
• Density: 1.541 g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: 2-8°C
• PKA: 15.39±0.40(Predicted)
• CAS DataBase Reference: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(98612-60-3)
• EPA Substance Registry System: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(98612-60-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 98612-60-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C5H8BrNO/c6-3-4-1-2-5(8)7-4/h4H,1-3H2,(H,7,8)/t4-/m1/s1

Upstream product

• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 6893-26-1 D-Glutamic acid 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 128899-31-0 <(2R)-5-oxopyrrolidin-2-yl>methyl 4-methylbenzenesulfonate 
• 64700-65-8 methyl (2R)-pyroglutamate 

Downstream Products

• 63328-11-0 (5R)-5-benzylpyrrolidin-2-one 
• 119603-16-6 majusculamide D 
• 98612-63-6 (-)-AKS 19 

Relevant articles and documents

Highly Convergent Total Synthesis and Assignment of Absolute Configuration of Majusculamide D, a Potent and Selective Cytotoxic Metabolite from Moorea sp.

The total synthesis of majusculamide D (MJS-D) is described, a lipopentapeptide originally isolated from Lyngbya majuscula and reisolated from a Moorea sp. MJS-D possesses selective and potent cancer cell toxicity. A scalable and convergent strategy with a minimal number of purifications produced significant quantities of MJM-D for in vivo evaluations. The absolute configuration of the 1,3-dimethyl-octanamide motif was determined by synthesis of this fragment via ZACA chemistry.

MUSCARINIC AGONISTS

This invention relates to compounds that are agonists of the muscarinic M4 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1a or a salt thereof, wherein n, p, Q, R1, R2, R3, R9 and R4 are as defined herein.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection of following Fomula (I). Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Developing microcolin A analogs as biological probes

Three microcolin A and B analogs have been synthesized. Their biological activity profiles were evaluated against several cell lines, revealing the existence of a structural determinant whose role in mediating the antiproliferative effect of the microcoli

12. Approaches to the Synthesis of Cytochalasans; Part 9: A Versatile Concept Leading To All Structural Types of Cytochalasans

Starting from D-glutamic acid (5), the bicyclic compounds 4a and 4b were synthesized via 17 (Schemes 1 and 2).The reaction leading to 4g and 4h with LiCuPh2 was not successful.But treatment of the N-protected model lactams 19, 21, and 22 with Li2Cu(CN)Ph2 gave the amino ketones 24, 26, and 26, respectively (Scheme 3).The desired compound 23 was obtained from 20.Conversion of the unprotected lactams 28, 31, and 32 gave the phenyl derivative 34 in excellent yields.Ester 35 was transformed to the α-amino-γ-oxo-acid derivative 36.This conversion opens a novel access to this type of compounds.